Skip to main content
IGMSacquired

IGM Biosciences, Inc.

Biopharma developer (SEC filing verified)·Commercial·CEO: Chief Executive Officer
OncologyNeurologyImmunologyInfectious DiseaseRespiratoryDermatologyNephrologyMusculoskeletalGastroenterologyEndocrinology

IGMS evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for IGMS—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

5.0/10

BioSniper Score

Based on 5 of 6 signals

Market Cap

—

Cash Runway

3.2 mo

Lead Asset

IGM-2644 (Phase 2)

Next Catalyst

Phase3_Topline · Jan 20, 2027

Financial data as of Jun 30, 2025.

Tracking 1 pipeline candidate · 86 clinical trials · 2 catalysts for IGM Biosciences, Inc..

Run IGM Biosciences, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available IGM Biosciences, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 5 of 6 signals · derived from public data

Cash Runway0.9

3.2 months

Financial Health9.8

D/E 0.06

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst Momentum5.0

2 upcoming, next in ~143d

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Run my thesis on this company

Catalysts

Run my thesis on this company

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Financials

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is IGM Biosciences, Inc.'s lead drug candidate?

IGM Biosciences, Inc.'s most advanced tracked candidate is IGM-2644 (Phase 2) for Autoimmune diseases targeting antibody-secreting plasma cells.

What is IGM Biosciences, Inc.'s next catalyst?

IGM Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: SBRT Combined With PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases: A Prospecti" — expected January 20, 2027.

Who is the CEO of IGM Biosciences, Inc.?

Chief Executive Officer is the chief executive officer of IGM Biosciences, Inc. (IGMS).

What therapeutic areas does IGM Biosciences, Inc. focus on?

IGM Biosciences, Inc. develops therapies across Oncology, Neurology, Immunology, Infectious Disease, Respiratory, Dermatology, Nephrology, Musculoskeletal, Gastroenterology, Endocrinology.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.